Michael Campos
Papers
2
Total Citations
381
H-Index
2
About
Michael Campos is a leading pulmonary researcher whose work centers on the respiratory health impacts of tobacco and electronic cigarette exposure, with a particular focus on chronic obstructive pulmonary disease (COPD) and mucociliary dysfunction. His most influential study, "Chronic electronic cigarette exposure in mice induces features of COPD in a nicotine-dependent manner" (2016, 343 citations), provided groundbreaking preclinical evidence that long-term e-cigarette use can trigger COPD-like pathology, directly challenging the perception of e-cigarettes as harmless alternatives. This work has become a cornerstone in the debate on vaping safety, cited extensively in toxicology and public health literature. In another key contribution, "Roflumilast partially reverses smoke-induced mucociliary dysfunction" (2015, 38 citations), Campos demonstrated that PDE4 inhibitors can restore airway clearance mechanisms impaired by smoking, offering a mechanistic rationale for therapeutic interventions in COPD. His research bridges molecular pharmacology and translational medicine, revealing how nicotine and smoke disrupt airway epithelial function via CFTR and cAMP signaling. Campos’s work has not only advanced fundamental understanding of smoking-related lung disease but also informed regulatory discussions on e-cigarette safety, making him a vital voice in respiratory health research.
Research Focus
Key Achievements
Top Papers
- 1
- 2Roflumilast partially reverses smoke-induced mucociliary dysfunction38 citations · 2015